Curcumin/Paclitaxel
Alternative Names: Paclitaxel/curcumin; STO-1Latest Information Update: 04 Jul 2025
At a glance
- Originator Vascarta
- Class Albumins; Analgesics; Anti-ischaemics; Antianaemics; Antihistamines; Antineoplastics; Antivirals; Catechols; Chemopreventatives; Diterpenes; Nonsteroidal anti-inflammatories; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Antioxidants; CCR2 receptor antagonists; Chemokine CCL 5 inhibitors; Cyclo-oxygenase 2 inhibitors; Cystic fibrosis transmembrane conductance regulator modulators; HIV integrase inhibitors; Immunosuppressants; Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Interleukin 8 inhibitors; Mast cell stabilisers; Mitosis inhibitors; Platelet aggregation inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Thromboxane synthase inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Glioblastoma
Most Recent Events
- 04 Jul 2025 Curcumin/Paclitaxel is available for licensing as of 04 Jul 2025. https://vascarta.com/partnering/
- 04 Jul 2025 Preclinical trials in Glioblastoma in USA (unspecified route) (Vascarta pipeline, July 2025)